After years of delay, Roche takes one of Spark’s hemophilia gene therapies into PhIII, drops another
As Roche finally puts one gene therapy for hemophilia A into Phase III, it’s discarding another.
Roche disclosed the removal of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
